Erythema multiforme and related disorders

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 103, Issue 5, 2007, Pages 642-654

  Al Johani, Khalid A ^a   Fedele, Stefano ^a   Porter, Stephen R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLASSIFICATION; DRUG HYPERSENSITIVITY; ERYTHEMA MULTIFORME; HUMAN; MOUTH MUCOSA; MOUTH ULCER; PATHOLOGY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIROLOGY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOUTH MUCOSA; ORAL ULCER; STEVENS-JOHNSON SYNDROME;

EID: 34247383565     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2006.12.008     Document Type: Article

References (176)

1. Katz J., Livneh A., Shemer J., Danon Y.L., and Peretz B. Herpes simplex-associated erythema multiforme (HAEM): a clinical therapeutic dilemma. Pediatr Dent 21 (1999) 359-362
2. Auquier-Dunant A., Mockenhaupt M., Naldi L., Correia O., Schroder W., Roujeau J.C., et al. Severe cutaneous adverse reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138 (2002) 1019-1024
3. Cote B., Wechsler J., Bastuji-Garin S., Assier H., Revuz J., and Roujeau J.C. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 131 (1995) 1268-1272
4. Assier H., Bastuji-Garin S., Revuz J., and Roujeau J.C. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 131 (1995) 539-543
5. Williams P.M., and Conklin R.J. Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis. Dent Clin North Am 49 (2005) 67-76
6. Bastuji-Garin, Rzany B., Stern R.S., Shear N.H., Naldi L., and Roujeau J.C. Clincal classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 (1993) 92-96
7. Huff J.C. Erythema multiforme. Dermatol Clin 3 (1985) 141-152
8. Huff J.C., Weston W.L., and Tonnesen M.G. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 8 (1983) 763-765
9. Rappersberger K., and Foedinger D. Treatment of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Dermatol Ther 15 (2002) 397-407
10. Sakurai M. Erythema multiforme in children: unusual clinical features with seasonal occurrence. J Dermatol 16 (1989) 361-368
11. Ginsburg C.M. Stevens-Johnson syndrome in children. Pediatr Infect Dis 1 (1982) 155-158
12. Brice S.L., Huff J.C., and Weston W.L. Erythema multiforme. Curr Probl Dermatol 2 (1990) 3-12
13. Hurwitz S. Erythema multiforme: a review of its characteristics, diagnostic criteria, and management. Pediatr Rev 11 (1990) 217-222
14. Micalizzi C., and Farris A. Erythema multiforme along Blaschko's lines. J Eur Acad Dermatol Venereol 14 (2000) 203-204
15. Lozada-Nur F., Gorsky M., and Silverman Jr. S. Oral erythema multiforme clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol 67 (1989) 36-40
16. Ayangco L., and Rogers III R.S. Oral manifestations of erythema multiforme. Dermatol Clin 21 (2003) 195-205
17. Weston W.L., Morelli J.G., and Rogers M. Target lesions on the lips: childhood herpes simplex associated with erythema multiforme mimics Stevens-Johnson syndrome. J Am Acad Dermatol 37 (1997) 848-850
18. Farthing P., Bagan J.V., and Scully C. Mucosal disease series. Number IV. Erythema multiforme. Oral Dis 11 (2005) 261-267
19. Leigh I.M., Mowbray J.F., Levene G.M., and Sutherland S. Recurrent and continuous erythema multiforme-a clinical and immunological study. Clin Exp Dermatol 10 (1985) 58-67
20. Drago F., Parodi A., and Rebora A. Persistent erythema multiforme: report of two new cases and review of literature. J Am Acad Dermatol 33 (1995) 366-369
21. Calzavara Pinton P.G., Venturini M., Capezzera R., Zane C., and Facchetti F. Photosensitive erythema multiforme and erythema multiforme-like polymorphous light eruption. Photodermatol Photoimmunol Photomed 19 (2003) 157-159
22. Huff J.C., and Weston W.L. Recurrent erythema multiforme. Medicine (Baltimore) 68 (1989) 133-140
23. Schofield J.K., Tatnall F.M., and Leigh I.M. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 128 (1993) 542-545
24. Davis M.D., Rogers III R.S., and Pittelkow M.R. Recurrent erythema multiforme/Stevens-Johnson syndrome response to mycophenolate mofetil. Arch Dermatol 138 (2002) 1547-1550
25. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
26. Sheridan R.L., Schulz J.T., Ryan C.M., Schnitzer J.J., Lawlor D., Driscoll D.N., et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 109 (2002) 74-78
27. Al-Ubaidy S.S., and Nally F.F. Erythema multiforme. Review of twenty-six cases. Oral Surg Oral Med Oral Pathol 41 (1976) 601-606
28. Kennett S. Erythema multiforme affecting the oral cavity. Oral Surg Oral Med Oral Pathol 25 (1968) 366-373
29. Farthing P.M., Maragou P., Coates M., Tatnall F., Leigh I.M., and Williams D.M. Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme. J Oral Pathol Med 24 (1995) 9-13
30. Bean S.F., and Quezada R.K. Recurrent oral erythema multiforme. Clinical experience with 11 patients. JAMA 249 (1983) 2810-2812
31. Gebel K., and Hornestein O.P. Drug-induced oral erythema multiforme. Results of a long-term retrospective study. Dermatologica 168 (1984) 35-40
32. Zweiban B., Cohen H., and Chandrasoma P. Gastrointestinal involvement complicating Stevens-Johnson syndrome. Gastroenterology 91 (1986) 469-474
33. Edmond B.J., Hu J.C., and Weston W.L. Erythema multiforme. Pediatr Clin N Am 30 (1983) 631-640
34. Nethercott J.R., and Choi B.C.K. Erythema multiforme (Stevens-Johnson syndrome)-charts of 123 hospitalized patients. Dermatologica 171 (1985) 383-396
35. Chan H.L. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol 10 (1984) 973-978
36. Roujeau J.C. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease, which differs from: erythema multiforme. J Dermatol 24 (1997) 726-729
37. Fritsch P.O., and Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 1 (2000) 349-360
38. Kasper M. Stevens-Johnson syndrome. Clin J Oncol Nurs 5 (2001) 25-26
39. Sneddon I.B. Subcorneal pustules in erythema multiforme. Br J Dermatol 88 (1973) 605-607
40. Tay Y.-K., Huff J.C., and Weston W.L. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (Von Hebra). J Am Acad Dermatol 35 (1996) 757-760
41. Furubacke A., Berlin G., Anderson C., and Sjoberg F. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?. Intensive Care Med 25 (1999) 1307-1310
42. Bachot N., Revuz J., and Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective non-comparative study showing no benefit on mortality or progression. Arch Dermatol 139 (2003) 33-36
43. Ghislain P.D., and Roujeau J.C. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 81 (2002) 5
44. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
45. Garcia-Doval I., Lecleach L., Bocquet H., Otero X.L., and Roujeau J.C. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 136 (2000) 323-327
46. Khoo A.K., and Foo C.L. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 22 (1996) 275-278
47. Carter F.M., and Mitchell C.K. Toxic epidermal necrolysis-an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum 36 (1993) 773-777
48. Chan H.L., Stern R.S., Arndt K.A., Langlois J., Jick S.S., Jick H., et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126 (1990) 43-47
49. Schwartz R.A. Toxic epidermal necrolysis. Cutis 59 (1997) 123-128
50. Schopf E., Stuhmer A., Rzany B., Victor N., Zentgraf R., and Kapp J.F. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 127 (1991) 839-842
51. Vanfleteren I., Van Gysel D., and De Brandt C. Stevens-Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Paediatric Dermatol 20 (2003) 52-56
52. Roujeau J.C., Chosidow O., Saiag P., and Guillaume J.C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23 (1990) 1039-1058
53. Rzany B., Mockenhaupt M., Baur S., Schroder W., Stocker U., Mueller J., et al. Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 149 (1996) 769-773
54. Brand R., and Rohr J.B. Toxic epidermal necrolysis in Western Australia. Australas J Dermatol 41 (2000) 31-33
55. Goldberg L.H., and Sperber J. Erythema multiforme due to herpes simplex: treatment with oral acyclovir. South Med J 79 (1986) 757-759
56. Kokuba H., Imafuku S., Huang S., Aurelian L., and Burnett J.W. Erythema multiforme lesions are associated with expression of a herpes simplex virus (HSV) gene and qualitative alterations in the HSV-specific T-cell response. Br J Dermatol 138 (1998) 952-964
57. Sun Y., Chan R.K., Tan S.H., and Ng P.P. Detection and genotyping of human herpes simplex viruses in cutaneous lesions of erythema multiforme by nested PCR. J Med Virol 71 (2003) 423-428
58. Imafuku S., Kokuba H., Aurelian L., and Burnett J. Expression of herpes simplex virus DNA fragments located in epidermal keratinocytes and germinative cells is associated with the development of erythema multiforme lesions. J Invest Dermatol 109 (1997) 550-556
59. Brice S.L., Krzemien D., Weston W.L., and Huff J.C. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J Invest Dermatol 74 (1989) 372-374
60. Lemak M.A., Duvic M., and Bean S.F. Oral acyclovir for the prevention of herpes-associated erythema multiforme. J Am Acad Dermatol 15 (1986) 50-54
61. Roujeau J.C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
62. Kamaliah M.D., Zainal D., Mokhtar N., and Nazmi N. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol 37 (1998) 520-523
63. Leaute-Labreze, Lamireau T., Chawki D., Maleville J., and Taïeb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnsonn syndrome. Arch Dis Child 83 (2000) 347-352
64. Yung A., Agnew K., Snow J., and Oliver F. Two unusual cases of toxic epidermal necrolysis. Australas J Dermatol 43 (2002) 35-38
65. Hockett K.C. Stevens-Johnson syndrome and toxic epidermal necrolysis: oncologic considerations. Clin J Oncol Nurs 8 (2003) 27-30
66. Leaute-Labreze C., Lamireau T., Chawki D., Maleville J., and Taieb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 83 (2000) 347-352
67. Guillaume J.C., Roujeau J.C., Revuz J., Penso D., and Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 123 (1987) 1166-1170
68. Roujeau J.C., Chosidow O., Saiag P., and Guillaume J.C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23 (1990) 1039-1058
69. Nanda A., and Kaur S. Drug-induced toxic epidermal necrolysis in developing countries. Arch Dermatol 126 (1990) 125
70. Kanwar A.J., Dogra S., and Kumar B. Changing pattern of drug-induced toxic epidermal necrolysis in developing countries. Clin Exp Dermatol 29 (2004) 425-426
71. Wong K.C., Kennedy P.J., and Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 40 (1999) 131-134
72. Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 1 (2000) 428-486
73. Larregue M., Pouvreau A., Prigent F., Lorette G., and Canuel C. Stevens-Johnson syndrome and pulmonary infection by Mycoplasma pneumonia. Sem Hop 58 (1982) 478-484
74. Kalb R.E., Grossman M.E., and Neu H.C. Stevens-Johnson syndrome due to Mycoplasma pneumoniae in an adult. Am J Med 79 (1985) 541-544
75. Salmon P., and Rademaker M. Erythema multiforme associated with an outbreak of Mycoplasma pneumoniae function. N Z Med J 106 (1993) 449-450
76. Levy M., and Shear N.H. Mycoplasma pneumoniae infections and Stevens-Johnson syndrome. Report of eight cases and review of the literature. Clin Pediatr (Phila) 30 (1991) 42-49
77. Stawiski M.A., and Ross L.R. Toxic epidermal necrolysis and mixed histiolymphocytic lymphoma. Cutis 28 (1981) 286-289
78. Hsiao L.T., Chung H.M., Lin J.T., Chiou T.J., Liu J.H., Fan F.S., et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 117 (2002) 620-622
79. Samimi S.S., and Siegfried E. Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy. Pediatr Dermatol 19 (2002) 52-55
80. Morelli M.S., and O Brien F.X. Stevens-Johnson Syndrome and cholestatic hepatitis. Dig Dis Sci 46 (2001) 2385-2388
81. Takeda H., Mitsuhashi Y., Kondo S., Kato Y., and Tajima K. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 24 (1997) 635-641
82. Rotunda A., Hirsch R.J., Scheinfeld N., and Weinberg J.M. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 83 (2003) 1-9
83. Cattelan A.M., Trevenzoli M., Sasset L., Sgarabotto D., Lanzafame M., and Meneghetti F. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature. J Infect 43 (2001) 246-249
84. Van der Ven A.J., Koopmans P.P., Vree T.B., and van der Meer J.W. Adverse reactions to co-trimoxazole in HIV infection. Lancet 338 (1991) 431-433
85. Saiag P., Caumes E., Chosidow O., Revuz J., and Roujeau J.C. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 26 (1992) 567-574
86. Pacheco H., Araujo T., and Kerdel F. Toxic epidermal necrolysis in a pregnant, HIV-infected woman. Int J Dermatol 41 (2002) 600-601
87. Ono F., Sharma B.K., Smith C.C., Burnett J.W., and Aurelian L. CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM). J Invest Dermatol 124 (2005) 1215-1224
88. Aurelian L., Ono F., and Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 9 (2003) 1
89. Kokuba H., Aurelian L., and Burnett J. Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol 113 (1999) 808-815
90. Spandau U., Brocker E.B., Kampgen E., and Gillitzer R. CC and CXC chemokines are differentially expressed in erythema multiforme in vivo. Arch Dermatol 138 (2002) 1027-1033
91. Foedinger D., Anhalt G., Boecskoer B., Elbe A., Wolff K., and Rappersberger K. Autoantibodies to desmoplakin I and II in patients with erythema multiforme. J Exp Med 181 (1995) 169-179
92. Foedinger D., Elbe-Burger A., Sterniczky B., Lackner M., Horvat R., Wolff K., et al. Erythema multiforme associated human autoantibodies against desmoplakin II and I: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol 111 (1998) 503-510
93. Matsuoka L.Y., Wortsman J., and Stanley J.R. Epidermal autoantibodies in erythema multiforme. J Am Acad Dermatol 21 (1989) 677-680
94. Paul C., Wolkenstein P., Adle H., Wechsler J., Garchon J.H., Revuz J., et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 134 (1996) 710-714
95. Abe R., Shimizu T., Shibaki A., Nakamura H., Watanabe H., and Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162 (2003) 1515-1520
96. Friedmann P.S., Strickland I., Pirmohamed M., and Park B.K. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 130 (1994) 598-604
97. Hertl M., Jugert F., and Merk H.F. CD8+ dermal T-cells from a sulfamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 132 (1995) 215-220
98. Roujeau J.C., Huynh T.N., Bracq C., Guillaume J.C., Revuz J., and Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123 (1987) 1171-1173
99. Correia O., Delgado L., Ramos J.P., Resende C., and Flemming Torrinha J.A. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 129 (1993) 466-468
100. Le Cleach L., Delaire S., Boumsell L., Bagot M., Bougault-Villada I., Bensussan A., et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells, which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 119 (2000) 225-230
101. Correia O., Delgado L., Barbosa I.L., Campilho F., and Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 47 (2002) 58-62
102. Nassif A., Bensussan A., Dorothee G., Mami-Chouaib F., Bachot N., Bagot M., et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 118 (2002) 728-733
103. Trent J.T., Kirsner R.S., Romanelli P., and Kerdel F.A. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 139 (2003) 39-43
104. Wehrli P., Viard I., Bullani R., Tschopp J., and French L.E. Death receptors in cutaneous biology and disease. J Invest Dermatol 115 (2000) 141-148
105. Snyder S.H., and Bredt D.S. Biological roles of nitric oxide. Sci Am 266 (1992) 68-77
106. Chlichlia K., Peter M.E., Rocha M., Scaffidi C., Bucur M., Krammer P.H., et al. Caspase activation is required for nitric oxide-mediated, CD95 (APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 91 (1998) 4311-4320
107. Paquet P., and Pierard G.E. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 19 (1997) 127-132
108. Bedi T.R., and Pinkus H. Histopathological spectrum of erythema multiforme. Br J Dermatol 95 (1976) 243-250
109. Larcher C., Gasser A., Hattmannstorfer R., Obexer P., Furhapter C., Fritsch P., et al. Interaction of HSV-1 infected peripheral blood mononuclear cells with cultured dermal microvascular endothelial cells: a potential model for the pathogenesis of HSV-1 induced erythema multiforme. J Invest Dermatol 116 (2001) 150-156
110. Patterson J.W., Parsons J.M., Blaylock W.K., and Mills A.S. Eosinophils in skin lesions of erythema multiforme. Arch Pathol Lab Med 113 (1989) 36-39
111. Howland W.W., Golitz L.E., Weston W.L., and Huff J.C. Erythema multiforme: clinical, histopathologic, and immunologic study. J Am Acad Dermatol 10 (1984) 438-446
112. Nishida K., Yamanishi K., Yamada K., Dota A., Kawasaki S., Quantock A.J., et al. Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva. Am J Pathol 154 (1999) 331-336
113. Halevy S., Cohen A.D., and Livni E. The diagnostic role of the in vitro drug-induced interferon-gamma release test in Stevens-Johnson syndrome. Int J Dermatol 38 (1999) 835-840
114. Wolkenstein P., Chosidow O., Flechet M.L., Robbiola O., Paul M., Dume L., et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35 (1996) 234-236
115. Shimizu S., Chen K.R., Pratchyapruit W.O., and Shimizu H. Tropical-wood-induced bullous erythema multiforme. Dermatology 200 (2000) 59-62
116. Halevi A., Ben-Amitai D., and Garty B.Z. Toxic epidermal necrolysis associated with acetaminophen ingestion. Ann Pharmacother 34 (2000) 32-34
117. Livni E., Lapidoth M., and Halevy S. In vitro release of interferon-gamma and macrophage migration inhibition factor in drug-induced urticaria and angioedema. Acta Derm Venereol 79 (1999) 18-22
118. Green J.A., Spruance S.L., Wenerstrom G., and Piepkorn M.W. Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir. Ann Intern Med 102 (1985) 632-633
119. Lynn W.A., Davidson R.N., and Wansbrough-Jones M.H. Successful use of oral acyclovir to prevent herpes simplex-associated erythema multiforme. J Infect 15 (1987) 192-193
120. Choy A.C., Yarnold P.R., Brown J.E., Kayaloglou G.T., Greenberger P.A., and Patterson R. Virus induced erythema multiforme and Stevens-Johnson syndrome. Allergy Proc 16 (1995) 157-161
121. Cheriyan S., and Patterson R. Recurrent Stevens-Johnson syndrome secondary to herpes simplex: a follow up on a successful management program. Allergy Asthma Proc 17 (1996) 71-73
122. Tatnall F.M., Schofield J.K., and Leigh I.M. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 132 (1995) 267-270
123. Molnar I., and Matulis M. Arthritis associated with recurrent erythema multiforme responding to oral acyclovir. Clin Rheumatol 21 (2002) 415-417
124. Kerob D., Assier-Bonnet H., Esnault-Gelly P., Blanc F., and Saiag P. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy. Arch Dermatol 134 (1998) 876-877
125. Brody I. Topical treatment of recurrent herpes simplex and post-herpetic erythema multiforme with low concentrations of zinc sulphate solution. Br J Dermatol 104 (1981) 191-194
126. Palmieri T.L., Greenhalgh D.G., Saffle J.R., Spence R.J., Peck M.D., Jeng J.C., et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23 (2002) 87-96
127. Jackel R., Fuchs M., Raff T., and Wiedemann B. Drug-induced toxic epidermal necrolysis with involvement of the intestinal and respiratory tract. A case report. Anaesthesist 51 (2002) 815-819
128. McGee T., and Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102 (1998) 1018-1022
129. Kelemen III J.J., Cioffi W.G., McManus W.F., Mason A.D., and Pruitt B.A. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 180 (1995) 273-278
130. Ruiz-Maldonado R. Acute disseminated epidermal necrolysis types 1, 2, and 3. Study of sixty cases. J Am Acad Dermatol 13 (1985) 623-625
131. Rzany B., Schmitt H., and Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 71 (1991) 171-172
132. Revuz J., Roujeau J.-C., Guillaume J.-C., Penso D., and Touraine R. Treatment of toxic epidermal necrolysis. Creteil's experience. Arch Dermatol 123 (1987) 1156-1158
133. Halebian P.H., Corder V.J., Madden M.R., Finklestein J.L., and Shires G.T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204 (1986) 503-512
134. Patterson R., Dykewicz M.S., Gonzalzles A., Grammer L.C., Green D., Greenberger P.A., et al. Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest 98 (1990) 331-336
135. Spies M., Sanford A.P., Aili Low J.F., Wolf S.E., and Herndon D.N. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 108 (2001) 1162-1168
136. Prendiville J.S., Hebert A.A., Greenwald M.J., and Esterly N.B. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 115 (1989) 881-887
137. Avakian R., Flowers F., Araujo O.E., and Ramos-Caro F.A. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 25 (1991) 69-79
138. Herndon D.N. Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 180 (1995) 340-342
139. Guibal G., Bastuji-Garin S., Chosidow O., Saiag P., Revuz J., and Roujeau J.C. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 131 (1995) 669-672
140. Heng M.C., and Allen S.G. Efficacy of cyclophoshamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects. J Am Acad Dermatol 25 (1991) 778-786
141. Frangogiannis N.G., Boridy I., Mazhar M., Mathews R., Gangopadhyay S., and Cate T. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 89 (1996) 1001-1003
142. Trautmann A., Klein C.E., Kampgen E., and Brocker E.B. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 139 (1998) 1127-1128
143. Arevalo J.M., Lorente J.A., Gonzales-Herrada C., and Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48 (2000) 473-478
144. Robak E., Robak T., Gora-Tybor J., Chojnowski K., Strzelecka B., Waszczykowska E., et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med 32 (2001) 31-39
145. Mahendran R., Grant J.W., and Norris P.G. Dapsone-responsive persistent erythema multiforme. Dermatology 200 (2000) 281-282
146. Berard F., Pincemaille B., Charhon A., and Perrot H. Persistent erythema multiforme associated with chronic hepatitis C virus infection. Efficacy of interferon alpha. Ann Dermatol Venereol 124 (1997) 329-331
147. Dumas V., Thieulent N., Souillet Al., Jullien D., Faure M., and Claudy A. Recurrent erythema multiforme and chronic hepatitis C: efficacy of interferon alpha. Br J Dermatol 142 (2000) 1248-1249
148. Wolkenstein P., Latarjet J., Roujeau J.C., Duguet C., Boudeau S., Vaillant L., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352 (1998) 1586-1589
149. Fischer M., Fiedler E., Marsch W.C., and Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 (2002) 707-709
150. Hunger R.E., Hunziker T., Buettiker U., Braathen L.R., and Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 116 (2005) 923-924
151. Prins C., Kerdel F.A., Padilla R.S., Hunziker T., Chimenti S., Viard I., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139 (2003) 26-32
152. Hebert A.A., and Bogle M.A. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol 50 (2004) 286-288
153. Tristani-Firouzi P., Petersen M.J., Saffle J.R., Morris S.E., and Zone J.J. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47 (2002) 548-552
154. Claes P., Wintzen M., Allard S., Simons P., De Coninck A., and Lacor P. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur J Intern Med 15 (2004) 255-258
155. Stella M., Cassano P., Bollero D., and Clemente A. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 203 (2001) 45-49
156. Paquet P., Jacob E., Damas P., and Pierard G.E. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 27 (2001) 652-655
157. Brown K.M., Silver G.M., Halerz M., Walaszek P., Sandroni A., and Gamelli R.L. Toxic epidermal necrolysis: does immunoglobulin make a difference?. J Burn Care Rehabil 25 (2004) 81-88
158. Bachot N., and Roujeau J.C. Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 3 (2003) 269-274
159. Schifferli J., Leski M., Favre H., Imbach P., Nydegger U., and Davies K. High-dose intravenous IgG treatment and renal function. Lancet 337 (1991) 457-458
160. Stahl M., and Schifferli J.A. The renal risks of high-dose intravenous immunoglobulin treatment. Nephrol Dial Transplant 13 (1998) 2182-2185
161. Matsumoto Y., Naniwa D., Banno S., and Sugiura Y. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher 2 (1998) 300-304
162. Egan C.A., Grant W.J., Morris S.E., Saffle J.R., and Zone J.J. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 40 (1999) 458-461
163. Bamichas G., Natse T., Christidou F., Stangou M., Karagianni A., Koukourikos S., et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 6 (2002) 225-228
164. Kamanabroo D., Schmitz-Landgraf W., and Czarnetzki B.M. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 121 (1985) 1548-1549
165. Lissia M., Figus A., and Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 58 (2005) 504-510
166. Velez A., and Moreno J.C. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol 46 (2002) 469-470
167. Inamo Y., Okubo T., Wada M., Fuchigami S., Hashimoto K., Fuchigami T., et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 127 (2002) 89-94
168. Ringheanu M., and Laude T.A. Toxic epidermal necrolysis in children-an update. Clin Pediatr (Phila) 39 (2000) 687-694
169. Rottermann E.M., Julia M.V., Rovira J., Pari F.J., and Morales L. Esophageal stenosis following Stevens-Johnson syndrome. Treatment with balloon dilation. Clin Pediatr (Phila) 29 (1990) 336-338
170. Power W.J., Ghoraishi M., Merayo-Lloves J., Neves R.A., and Foster C.S. Analysis of the acute ophthalmic manifestations of the erythema multiforme/ Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 102 (1995) 1669-1676
171. Lebargy F., Wolkenstein P., Gisselbrecht M., Lange F., Fleury-Feith J., Delclaux C., et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23 (1997) 1237-1244
172. Forman R., Koren G., and Shear N.H. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 25 (2002) 965-972
173. Dawe S., Bentley R., and Creamer D. Toxic epidermal necrolysis complicated by delayed mucosal healing and haemorrhagic mucositis. Clin Exp Dermatol 28 (2003) 454-455
174. Magina S., Lisboa C., Leal V., Palmares J., and Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 207 (2003) 33-36
175. Agrawal A., Bramble M.G., Shehade S., and Dean J. Oesophageal stricturing secondary to adult Stevens-Johnson syndrome: similarities in presentation and management to corrosive injury. Endoscopy 35 (2003) 454-456
176. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau J.C., Revuz J., and Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115 (2000) 149-153